MX2009006529A - Formas cristalinas de ilaprazol solvatado. - Google Patents

Formas cristalinas de ilaprazol solvatado.

Info

Publication number
MX2009006529A
MX2009006529A MX2009006529A MX2009006529A MX2009006529A MX 2009006529 A MX2009006529 A MX 2009006529A MX 2009006529 A MX2009006529 A MX 2009006529A MX 2009006529 A MX2009006529 A MX 2009006529A MX 2009006529 A MX2009006529 A MX 2009006529A
Authority
MX
Mexico
Prior art keywords
ilaprazole
crystalline forms
methyl
relates
gastric acid
Prior art date
Application number
MX2009006529A
Other languages
English (en)
Spanish (es)
Inventor
John M Brackett
David T Jonaitis
Wei Lai
Stephan D Parent
Original Assignee
Il Yang Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharmaceutical Company filed Critical Il Yang Pharmaceutical Company
Publication of MX2009006529A publication Critical patent/MX2009006529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2009006529A 2006-12-29 2007-12-28 Formas cristalinas de ilaprazol solvatado. MX2009006529A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87760806P 2006-12-29 2006-12-29
US88749907P 2007-01-31 2007-01-31
PCT/US2007/089137 WO2008083341A1 (en) 2006-12-29 2007-12-28 Crystalline forms of solvated ilaprazole

Publications (1)

Publication Number Publication Date
MX2009006529A true MX2009006529A (es) 2009-08-18

Family

ID=39313094

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009006529A MX2009006529A (es) 2006-12-29 2007-12-28 Formas cristalinas de ilaprazol solvatado.
MX2009006530A MX2009006530A (es) 2006-12-29 2007-12-28 Formas de estado solido de ilaprazol racemico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009006530A MX2009006530A (es) 2006-12-29 2007-12-28 Formas de estado solido de ilaprazol racemico.

Country Status (18)

Country Link
US (4) US7999110B2 (enExample)
EP (2) EP2102192B1 (enExample)
JP (2) JP5315253B2 (enExample)
KR (3) KR20110091594A (enExample)
CN (2) CN101687849B (enExample)
AU (2) AU2007341984B2 (enExample)
CA (2) CA2674358C (enExample)
DK (1) DK2102192T3 (enExample)
ES (1) ES2398846T3 (enExample)
IL (2) IL199242A (enExample)
MX (2) MX2009006529A (enExample)
MY (2) MY145936A (enExample)
NO (2) NO20092398L (enExample)
NZ (2) NZ577509A (enExample)
PL (1) PL2102192T3 (enExample)
PT (1) PT2102192E (enExample)
RU (2) RU2464270C2 (enExample)
WO (2) WO2008083341A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144600B1 (ko) * 2009-12-08 2012-05-16 일양약품주식회사 일라프라졸의 결정형 ａ, ｂ의 제조방법 및 이들 결정형의 변환방법
CN103204843B (zh) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
CN103204842B (zh) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
WO2013114232A1 (en) * 2012-02-02 2013-08-08 Lupin Limited Process for preparation of crystalline form l of ilaprazole
CN102746275B (zh) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN102746277B (zh) * 2012-06-21 2014-05-14 丽珠医药集团股份有限公司 一种结晶形式的艾普拉唑钠及其制备方法
CN103172618B (zh) * 2013-02-27 2014-09-03 丽珠医药集团股份有限公司 艾普拉唑晶型及其制备方法
CN104370886B (zh) * 2014-11-18 2016-05-18 宁夏康亚药业有限公司 艾普拉唑晶型及其制备方法和应用
CN105055342A (zh) * 2015-08-13 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂
CN105055343A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物艾普拉唑钠组合物冻干粉针剂
CN106749191A (zh) * 2016-12-10 2017-05-31 珠海保税区丽珠合成制药有限公司 艾普拉唑晶型ⅱ及其制备方法
KR101961028B1 (ko) * 2017-10-12 2019-03-21 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 급성 위염의 예방 또는 치료용 약학 조성물
KR102332996B1 (ko) * 2020-04-13 2021-12-01 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 장폐색증 예방 또는 치료용 약학조성물
KR20220065235A (ko) 2020-11-13 2022-05-20 주식회사 파마코스텍 일라프라졸 혼형 결정의 신규한 제조방법
KR102250509B1 (ko) 2020-12-09 2021-05-11 유니셀랩 주식회사 새로운 일라프라졸/자일리톨 공결정
KR20210019469A (ko) 2021-02-02 2021-02-22 주식회사 파마코스텍 일라프라졸 나트륨 결정형 및 신규한 제조방법
CN117050060A (zh) * 2023-07-20 2023-11-14 浙江美诺华药物化学有限公司 一种艾普拉唑晶型f的制备方法
KR20250156870A (ko) 2024-04-25 2025-11-04 엠에프씨 주식회사 일라프라졸 마그네슘염 수화물의 제조방법
CN119462610A (zh) * 2024-11-06 2025-02-18 甘肃皓天科技股份有限公司 一种艾普拉唑新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
RU2232159C2 (ru) * 1999-07-29 2004-07-10 Регентский Совет Университета Калифорнии Производные бензимидазола и фармацевтические композиции, содержащие пролекарство ингибитора протонного насоса
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2003224779A1 (en) 2002-03-27 2003-10-13 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
ES2375298T3 (es) 2005-03-25 2012-02-28 Livzon Pharmaceutical Group Inc. Procedimiento para preparar derivados de sulfóxido sustituidos.
WO2006118534A1 (en) * 2005-05-04 2006-11-09 Astrazeneca Ab Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux

Also Published As

Publication number Publication date
US20110046184A1 (en) 2011-02-24
EP2102191B1 (en) 2012-11-21
HK1140483A1 (en) 2010-10-15
DK2102192T3 (da) 2013-03-04
MY146462A (en) 2012-08-15
US7989632B2 (en) 2011-08-02
CA2674358C (en) 2013-10-08
AU2007341992B2 (en) 2012-07-05
US7999110B2 (en) 2011-08-16
NO20092398L (no) 2009-09-28
CN101687849B (zh) 2013-05-29
EP2102192A1 (en) 2009-09-23
NZ577509A (en) 2012-01-12
CN101687849A (zh) 2010-03-31
US20110082174A1 (en) 2011-04-07
EP2102191A1 (en) 2009-09-23
MX2009006530A (es) 2009-08-18
WO2008083341A1 (en) 2008-07-10
WO2008083333A1 (en) 2008-07-10
IL199242A (en) 2013-10-31
CA2674347A1 (en) 2008-07-10
JP2010514806A (ja) 2010-05-06
US8592600B2 (en) 2013-11-26
AU2007341984B2 (en) 2012-07-05
HK1140484A1 (en) 2010-10-15
CN101687848B (zh) 2013-05-15
CA2674358A1 (en) 2008-07-10
RU2466129C2 (ru) 2012-11-10
CN101687848A (zh) 2010-03-31
RU2009122242A (ru) 2011-02-10
KR20090086121A (ko) 2009-08-10
AU2007341992A1 (en) 2008-07-10
MY145936A (en) 2012-05-31
JP5315253B2 (ja) 2013-10-16
RU2464270C2 (ru) 2012-10-20
KR20110091594A (ko) 2011-08-11
US20080200517A1 (en) 2008-08-21
KR20090086615A (ko) 2009-08-13
JP2010514807A (ja) 2010-05-06
JP5315254B2 (ja) 2013-10-16
PL2102192T3 (pl) 2013-04-30
NZ577129A (en) 2012-02-24
ES2398846T3 (es) 2013-03-22
NO20092464L (no) 2009-09-28
RU2009122241A (ru) 2011-02-10
US8592599B2 (en) 2013-11-26
IL199234A (en) 2013-07-31
CA2674347C (en) 2013-08-06
US20080200516A1 (en) 2008-08-21
KR101052387B1 (ko) 2011-07-28
EP2102192B1 (en) 2012-11-14
AU2007341984A1 (en) 2008-07-10
PT2102192E (pt) 2013-01-23
NO342530B1 (no) 2018-06-11

Similar Documents

Publication Publication Date Title
MX2009006529A (es) Formas cristalinas de ilaprazol solvatado.
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
ZA200709745B (en) Compositions and methods for inhibiting gastric acid secretion
UA89812C2 (ru) Замещенные пиридинильные и пиримидинильные производные, которые применяют как модуляторы метаболизма и для лечения ассоциированных с ним расстройств
PH12012500954A1 (en) Method for producing dabigatran etexilate
WO2009016462A3 (en) Substituted bicyclolactam compounds
PL2019683T3 (pl) Podawanie czynników wzrostu do leczenia zaburzeń OUN
WO2007118653A3 (de) Nanopartikel, enthaltend nicotin und/oder cotinin, dispersionen und die verwendung derselben
WO2007134678A3 (de) Triazolderivate ii
MY145632A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
JO2645B1 (en) Vehicles
WO2009158431A3 (en) Pyrimidine derivatives as kinase inhibitors
WO2008050199A3 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
MX2009000080A (es) Derivados de bencimidazol como inhibidores selectivos de la bomba de acido.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2009156041A3 (de) Thiazolyl-piperidinderivate
MX360150B (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
MY161425A (en) 6-substituted phenoxychroman carboxylic acid derivatives
WO2008131946A3 (de) Substituierte amid-derivate
WO2007109799A3 (en) Polymorphs of eszopiclone malate
WO2008011483A3 (en) Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
WO2007138468A3 (en) Processes for the preparation of lansoprazole
GB0611907D0 (en) Compounds

Legal Events

Date Code Title Description
FG Grant or registration